Trials / Completed
CompletedNCT00802828
Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions
Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Perrigo Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famotidine Tablets, 40 mg |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2004-06-01
- First posted
- 2008-12-05
- Last updated
- 2012-03-16
Source: ClinicalTrials.gov record NCT00802828. Inclusion in this directory is not an endorsement.